OncoLink Cancer Treatment and Resources

OncoLink Blogs
English Donar
Oncolink Features

Find My Cancer Drug

ABCDEF
GHILMN
OPRSTV


Librera OncoLink   /   Repaso de Diarios   /   Cáncer Gastrointestinal

Link to OncoLink

Phase II Trial of the combination of Paclitaxel and 5-Fluorouracil in the Treatment of Advanced Gastric Cancer ? A Novel, Safe, and Effective Regimen

Imprima English

Andre M. Murad, Andy Petroianu, Rodrigo C. Guimaraes, et al.
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001

Reviewers: Li Liu, MD
Source: American Journal of Clinical Oncology, 22(6):580-586, December 1999.


Précis: So far, the combination of paclitaxel and 5-fluorouracil have appeared to be very effective and safe in patients with advanced gastric cancer. More studies are necessary.

Introduction

Gastric cancer is the 9th leading cause of cancer related death in the United States, and second in the world. Curative surgery is the mainstay of treatment whenever the tumor is resectable. Adjuvant therapies have been investigated extensively for more than 30 years. Dr. Andre M. Murad and colleagues from Hospital das Clinicas in Brazil conducted this phase II study to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil (5-FU) in the treatment of advanced gastric adenocarcinoma.

Method

A total of 31 patients with locally unresectable or metastatic gastric carcinoma received up to 7 cycles of paclitaxel and 5-FU. 29 patients were eligible for response and toxicity evaluation.

Results

  • At 4 months, 24.1% of patients had complete responses and 41.4% had partial responses, and 51% of patients had improvement in quality of life.

  • Median survival was 12 months and 30-month survival was 20%.

  • There were no serious toxicities or deaths associated with this treatment.

Discussion

The combination of paclitaxel and 5-fluorouracil appeared to be very effective and safe in patients with advanced gastric cancer. Phase III randomized studies are warranted to confirm the real merit of this novel regimen.

OncoLink I wish u knew...

Dr. Metz talks about how caring for cancer patients has affected his life. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS

Mapa de Sitio   |   Contactar OncoLink   |   Declaración de Privacidad   |   Responsabilidad Legal   |   Enlace a OncoLink   |   Início
Para la ayuda visite por favor nuestro Sección de la AYUDA

Trustees of the University of Pennsylvania